Triglyceride metabolism in pregnancy

Author(s): Ghio A, Bertolotto A, Resi V, Volpe L, Di Cianni G

Abstract

During pregnancy, complex changes occur in lipid profiles. From the 12th week of gestation, phospholipids, cholesterol (total, LDL, HDL), and triglycerides (TG) increase in response to estrogen stimulation and insulin resistance. Transition to a catabolic state favors maternal tissue lipid use as energy sources, thus sparing glucose and amino acids for the fetus. In addition, maternal lipids, that is, cholesterol, are available for fetal use in building cell membranes and as precursor of bile acids and steroid hormones. It is also required for cell proliferation and development of the growing body. Free-fatty acids (FFA), oxidized in the maternal liver as ketone-bodies, represent an alternative fuel for the fetus. Maternal hypertriglyceridemia (vs. other lipids) has many positive effects such as contributing to fetal growth and development and serving as an energy depot for maternal dietary fatty acids. However, increased TG during pregnancy appears to increase risk of preeclampsia and preterm birth. Some have suggested that maternal hypertriglyceridemia has a role in increasing cardiovascular risk later in life. This chapter reviews lipid metabolism during pregnancy to elucidate its effect on fetal growth and its potential role in pregnancy-associated complications and future cardiovascular risk.

Similar Articles

Energy metabolism during human pregnancy

Author(s): Forsum E, Löf M

Clinical and biochemical features of fatty acid oxidation disorders

Author(s): Rinaldo P, Raymond K, al-Odaib A, Bennett MJ

Plasma carnitine levels of pregnant adolescents in labor

Author(s): Koumantakis E, Sifakis S, Koumantaki Y, Hassan E, Matalliotakis I, et al.

Pregnancy-related changes of carnitine and acylcarnitine concentrations of plasma and erythrocytes

Author(s): Schoderbeck M, Auer B, Legenstein E, Genger H, Sevelda P, et al.

Carnitine status and lactate increase in patients with type I juvenile diabetes

Author(s): Evangeliou A, Gourgiotis D, Karagianni C, Markouri M, Anogianaki N, et al.

The effect of the mode of delivery on the maternal-neonatal carnitine blood levels and antioxidant status

Author(s): Schulpis KH, Papakonstantinou ED, Vlachos GD, Vlachos DG, Antsaklis A, et al.

Current understanding of placental fatty acid transport

Author(s): Gil-Sánchez A, Koletzko B, Larqué E

Maternal lipid metabolism and placental lipid transfer

Author(s): Herrera E, Amusquivar E, López-Soldado I, Ortega H

Blood ketone monitoring: a comparison between gestational diabetes and non-diabetic pregnant women

Author(s): Gin H, Vambergue A, Vasseur C, Rigalleau V, Dufour P, et al.

Determination of free L-carnitine levels in type II diabetic women with and without complications

Author(s): Poorabbas A, Fallah F, Bagdadchi J, Mahdavi R, Aliasgarzadeh A, et al.

Oxidative metabolism in insulin-treated gestational diabetes mellitus

Author(s): Hsu HW, Butte NF, Wong WW, Moon JK, Ellis KJ, et al.

Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta

Author(s): Grube M, Meyer Zu Schwabedissen H, Draber K, Präger D, Möritz KU, et al.

High activity of fatty acid oxidation enzymes in human placenta: implications for fetal-maternal disease

Author(s): Oey NA, den Boer ME, Ruiter JP, Wanders RJ, Duran M, et al.

Long-chain fatty acid oxidation during early human development

Author(s): Oey NA, den Boer ME, Wijburg FA, Vekemans M, Augé J, et al.